Cartalax

Cartalax is a tripeptide bioregulator (Ala-Glu-Asp) developed by the St. Petersburg Institute of Bioregulation and Gerontology. It is a tissue-specific peptide designed to support cartilage and connective tissue health. Research from Russian institutes suggests it stimulates chondrocyte function, promotes cartilage matrix synthesis, and may help restore joint integrity in aging or injury-related cartilage degeneration.

— 20 mg Vial —

Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL concentration.
Example daily range: 2,000–5,000 mcg once daily (gradual titration).
Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U-100 insulin syringe.
Storage: Lyophilized: refrigerate at 2–8 °C or freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, avoid freeze-thaw cycles.

Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Cycle Length: 8–12 weeks; optional extension to 16 weeks.
Goal: Support connective-tissue homeostasis and fibroblast function based on preclinical bioregulator research.

10-20 day cycle. Repeat 3-4 times per year.

Subcutaneous Administration

Mix with 2mL (200 units) of BAC

Standard Protocol

20 units (2mg), 1x/day, for 20 days.

Low Dose Protocol

10 units (1mg), 1x/day, for 10-20 days

• Supports chondrocyte proliferation and function
• Promotes synthesis of collagen and proteoglycans in cartilage
• May reduce cartilage degradation in osteoarthritis models
• Supports connective tissue health and joint integrity
• Anti-aging effects on cartilage tissue
• Well-tolerated peptide bioregulator
• May be used alongside other joint-supporting peptides (BPC-157, TB-500)

Cartalax (Ala-Glu-Asp) functions as a gene expression regulator in chondrocytes and connective tissue cells. As a short peptide bioregulator, it is hypothesized to penetrate cell nuclei and interact with chromatin, modulating gene expression of proteins involved in extracellular matrix synthesis (collagen II, aggrecan) and chondrocyte proliferation. This targeted epigenetic mechanism supports tissue-specific restoration without systemic hormonal effects.

• Generally very well tolerated
• Mild injection site reactions
• No significant systemic side effects in available research

Standard peptide bioregulator tolerability management. Site rotation for subcutaneous injections. Well-tolerated by most research subjects in available studies.

• Known hypersensitivity to the peptide
• Pregnancy and lactation (insufficient safety data)

• Khavinson VK et al. (2010). Peptide regulation of aging. Biochemistry (Moscow). DOI: 10.1134/S0006297910130109
• Khavinson V et al. (2021). Short peptides and their role in tissue-specific regulation of aging. International Journal of Molecular Sciences. DOI: 10.3390/ijms22126239